Gilead's cell therapy product sales decreased 11% to $432 million in the third quarter of 2025, compared to the same period in 2024, primarily due to lower demand and competitive headwinds13457.
Yescarta sales were down 10% to $349 million, and Tecartus sales declined 15% to $83 million, reflecting continued softness in demand for Gilead's CAR T cell therapies12.
In contrast, Gilead's HIV franchise saw robust growth, with total HIV drug sales rising 4% year-over-year to $5.3 billion, led by a 6% increase for Biktarvy ($3.7 billion)126.
Yeztugo, a new twice-yearly HIV pre-exposure prophylaxis, reported $39 million in sales in its first commercial quarter126.
The company's overall revenue for Q3 2025 was $7.8 billion (up 3%), but total product sales dipped 2% to $7.3 billion, partly attributed to declines in cell therapy and COVID-19 drug (Veklury, down 60% to $277 million) sales12.
Other notable performers included Trodelvy in oncology, up 7% to $357 million, and liver disease drug Livdelzi, driving hepatology franchise growth127.
Sources:
1. https://investors.gilead.com/files/doc_financials/2025/q3/GILD-Q325-Earnings-Press-Release-30-October-2025.pdf
2. https://www.biospace.com/business/gilead-still-hungry-for-deals-as-hiv-portfolio-grows-veklury-crashes
3. https://dijee.net/commercial-medical/gilead-sees-cell-therapy-sales-decline-in-q3/
4. https://firstwordpharma.com/story/6512095
5. https://investors.gilead.com/news/news-details/2025/Gilead-Sciences-Announces-Third-Quarter-2025-Financial-Results/default.aspx
6. https://finimize.com/content/gilead-sciences-hiv-drug-sales-lead-a-strong-quarter
7. https://investors.gilead.com/files/doc_financials/2025/q3/GILD-Q325-Earnings-Presentation-30-October-2025.pdf